Home Online Advertising With Pharma’s Ability To Target Limited, Precision Health Prescribes Regimen Of Context And Geography

With Pharma’s Ability To Target Limited, Precision Health Prescribes Regimen Of Context And Geography

SHARE:

Precision Health Media is one of a large number of ad tech companies that began life as a vertical ad network and have been trying to evolve into a broader “platform.” The New York-based company still has many of the attributes of an ad network — it was initially known as Good Health Media when it was launched four years ago with ad serving powered by Adify — such as representing 280 health sites.

As the company looks to build out some self-serve ad functions next year, the concentration right now involves sharpening its focus as a contextual/semantic provider, promising to match advertisers and agencies with sites that have shown they can directly reach allergy sufferers or those afflicted by, or deeply interested in, specific diseases like diabetes or multiple sclerosis.

“If a brand just wanted to reach those consumers looking into type-1 diabetics, we could find that kind of content by going through the 280 sites in our system,” says Bill Jennings, Precision Health’s CEO, in an interview with AdExchanger. “But we don’t just rely on semantics. For example, with diabetes, there happens to be an obvious belt of six or seven states with a higher than average incidence of the disease, so we’ll test inventory heavily against site readers in those areas. With pollen count, it’s the same thing, as we’ll target placements to readers in locations where allergy issues are trending.”

For the most part, behavioral targeting is off-limits to pharmaceutical marketers, Jennings notes. On average, Precision Health claims that its ConditionMatch contextual ad product delivers a click-through rate 40 percent higher than the industry average. It also claims that tests by a “major pharmaceutical marketer” — it wouldn’t identify the company — showed that ConditionMatch lowered cost-per-visit by 71 percent. Furthermore, Jennings points to ConditionMatch’s use of four years worth of site data, which allows the company to track the historical performance of a particular URL when it runs a specific kind of ad.

“The Interactive Advertising Bureau and other groups have agreed that drug companies should be tracking consumers’ illnesses or medical problems directly. It makes sense. And from a practical standpoint, it forces advertisers to do better forms of targeting to get to the right audience. For example, our advertisers are up to 50 percent more likely to reach a consumer who has filled a prescription when compared to targeting general health portals, such as WebMD.”

One of the biggest problems agencies with niche health conditions have is finding enough inventory. Again, because of the limited behavioral targeting options, audience buying is hindered to some extent. “If you think about conditions like gout, COPD, or MS, they might have to contact 12 to 18 sites individually to find the inventory. So we’re positioning ConditionMatch as a way to aggregate our sites’ collective 57 million monthly users and become a one-stop shop for media buyers.”

Must Read

Intent IQ Has Patents For Ad Tech’s Most Basic Functions – And It’s Not Afraid To Use Them

An unusual dilemma has programmatic vendors and ad tech platforms worried about a flurry of potential patent infringement suits.

TikTok Video For Open Web Publishers? Outbrain Built It.

Outbrain is trying to shed its chumbox rep by bringing social media-style vertical video to mobile publishers on the open web.

Billups Launches Attention Measurement For Out-Of-Home

Billups, a managed services agency that specializes in OOH, is making its attention measurement solution and a related analytics dashboard available for general use.

Privacy! Commerce! Connected TV! Read all about it. Subscribe to AdExchanger Newsletters
US District Court for the Eastern District of Virginia, Alexandria

The Google Ad Tech Antitrust Case Is Over – And Here’s What’s Happening Next

Just three weeks after it began, the Google ad tech antitrust trial in Virginia is over. The court will now take a nearly two-month break before reconvening for closing arguments right before Thanksgiving.

Jounce Media's Chris Kane at Programmatic IO NY on Sept. 25, 2024.

The Bidstream Is A Duplicative, Chaotic Mess – But It Doesn’t Have To Be That Way

Publishers are initiating more and more auctions – but doesn’t mean DSPs are listening to more bids, according to Chris Kane.

Readers Are Flocking To Political News, Says WaPo – And Advertisers Are Missing Out

During certain periods this year, advertisers blocked more than 40% of The Washington Post’s inventory over brand safety concerns.